跨国药企濒临3000亿美元专利悬崖

Core Insights - Major multinational pharmaceutical companies, including Johnson & Johnson, Roche, and Eli Lilly, have reported their 2025 earnings, showcasing a mix of growth and challenges in the industry [1][2][4][6][9]. Company Performance - Johnson & Johnson: Achieved total revenue of $94.193 billion, a 6% year-over-year increase, with the innovative pharmaceutical segment contributing 64% of total revenue [1][6]. The oncology sector generated $25.38 billion, growing at 22.1% [6]. - Roche: Reported revenue of $74.38 billion, up 7% year-over-year, with the pharmaceutical division earning $57.63 billion, a 9% increase [1][9]. Oncology remains a key revenue driver, contributing $28.963 billion [9]. - Eli Lilly: Emerged as a standout performer with $65.179 billion in revenue, a remarkable 45% increase, driven primarily by the success of the tirzepatide products [1][4]. The company anticipates 2026 revenue between $80 billion and $83 billion, reflecting a growth forecast of 23%-28% [4]. - Merck (MSD): Reported $65.01 billion in revenue, a modest 1% increase, with Keytruda sales reaching $31.7 billion, growing only 7% [1][12]. The company is facing challenges with declining sales of its HPV vaccine [12]. - Novartis: Achieved $54.53 billion in revenue, an 8% increase, with significant growth in its oncology and cardiovascular segments [1][14]. The CEO's compensation rose significantly, reflecting the company's strong stock performance [15]. - Novo Nordisk: Reported revenue of approximately $48.9 billion, a 6% increase, driven by the strong performance of semaglutide products [1][17]. However, the company has lowered its 2026 outlook due to patent cliff concerns [17]. - AstraZeneca: Generated $58.739 billion in revenue, an 8% increase, with oncology contributing 44% of total revenue [1][18]. The company plans to invest significantly in China, viewing it as a key market [18]. - Sanofi: Reported revenue of approximately $50.78 billion, a 9.9% increase, with Dupixent being a major growth driver [1][20]. The company is focusing on reducing dependency on Dupixent and expanding its product pipeline [21]. - Pfizer: Reported $62.579 billion in revenue, a 2% decline, but a 6% increase when excluding COVID-19 product impacts [1][22]. The company is focusing on R&D in key therapeutic areas for future growth [24]. Industry Trends - The pharmaceutical industry is experiencing stable growth overall, but faces significant challenges from patent expirations, with nearly 200 drugs expected to lose patent protection in the coming years, potentially resulting in over $300 billion in lost sales [2].